Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000437
Status:
COMPLETED
Last Update Posted:
2017-04-20
First Post:
1999-11-02
Brief Title:
Tobacco Dependence in Alcoholism Treatment Nicotine PatchNaltrexone
Sponsor:
The Scripps Research Institute
Organization:
The Scripps Research Institute
Study Overview
Official Title:
Nalmefene in Nicotine and Alcohol Dependence
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness of naltrexone Revia or matched placebo combined with nicotine patch Nicotrol or placebo patch using a 2x2 design in reducing drinking and smoking in patients with both nicotine and alcohol dependence
Detailed Description:
Eligible individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either naltrexone Revia and nicotine replacement patch or placebos All individuals will receive weekly coping skills and smoking-cessation behavioral therapy Followup interviews will be conducted 3 and 6 months after treatment to determine smoking and drinking status and persistence of any dependence symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01AA011210 | NIH | None | httpsreporternihgovquickSearchR01AA011210 |